Chronic Obstructive Pulmonary Disease (COPD) following acute exacerbation Chronic Obstructive Pulmonary Disease, N-acetylcysteine, Ambroxol, Mucolytic Agents, Cough, COPD Assessment Test
Conditions
Interventions
N-acetylcysteine 200 mg was administered orally three times daily for 14 days in addition to standard COPD therapy following hospitalization for an acute exacerbation.,Ambroxol 30 mg was administered
Active Comparator Drug,Active Comparator Drug
N-Acetylcysteine,Ambroxol
Sponsors
Universitas Gadjah Mada
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients aged 40 years and older with a diagnosis of acute exacerbation of chronic obstructive pulmonary disease who had been hospitalized and continued outpatient treatment 2. Patients who received either N-acetylcysteine or ambroxol as additional therapy after hospitalization 3. Patients who were able to communicate and complete study questionnaires 4. Patients who agreed to participate and provided written informed consent
Exclusion criteria
Exclusion criteria: 1. Patients with clinical diagnoses of lung cancer, bronchiectasis, tuberculosis, or interstitial lung disease 2. Patients with severe hepatic disorders, renal disorders, psychiatric disorders, hematologic disorders, or malignancy that could interfere with study participation based on medical record evaluation 3. Patients receiving other cough medications outside the assigned intervention during the study period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cough symptom severity At baseline and 14 days after intervention Cough Symptom Score questionnaire assessing daytime and nighttime cough symptoms | — |
Secondary
| Measure | Time frame |
|---|---|
| Health status in patients with chronic obstructive pulmonary disease At baseline and 30 days after intervention COPD Assessment Test questionnaire | — |
Countries
Indonesia
Contacts
Public ContactLuthfiah Pertiwi
Universitas Gadjah Mada
Outcome results
None listed